Lee Hambright
Stock Analyst at Bernstein
(3.01)
# 2,476
Out of 5,182 analysts
40
Total ratings
46.67%
Success rate
0.99%
Average return
Main Sectors:
Stocks Rated by Lee Hambright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Outperform | $380 → $330 | $204.31 | +61.52% | 3 | Feb 19, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $154 → $125 | $102.87 | +21.51% | 7 | Jan 23, 2026 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $740 → $750 | $452.07 | +65.90% | 4 | Jan 23, 2026 | |
| MDLN Medline | Initiates: Outperform | $49 | $44.28 | +10.66% | 1 | Jan 12, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Market Perform | $97 → $99 | $90.89 | +8.92% | 2 | Jan 9, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Market Perform | $18 → $25 | $18.61 | +34.34% | 2 | Jan 9, 2026 | |
| SYK Stryker | Maintains: Outperform | $450 → $465 | $331.54 | +40.25% | 4 | Jan 9, 2026 | |
| MDT Medtronic | Maintains: Outperform | $111 → $112 | $86.63 | +29.29% | 4 | Jan 9, 2026 | |
| JNJ Johnson & Johnson | Maintains: Market Perform | $193 → $208 | $243.04 | -14.42% | 6 | Jan 9, 2026 | |
| DXCM DexCom | Maintains: Outperform | $84 → $86 | $62.22 | +38.22% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $92 → $100 | $62.82 | +59.18% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $132 → $135 | $81.05 | +66.56% | 3 | Mar 16, 2022 |
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $380 → $330
Current: $204.31
Upside: +61.52%
Abbott Laboratories
Jan 23, 2026
Maintains: Outperform
Price Target: $154 → $125
Current: $102.87
Upside: +21.51%
Intuitive Surgical
Jan 23, 2026
Maintains: Outperform
Price Target: $740 → $750
Current: $452.07
Upside: +65.90%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $49
Current: $44.28
Upside: +10.66%
Zimmer Biomet Holdings
Jan 9, 2026
Maintains: Market Perform
Price Target: $97 → $99
Current: $90.89
Upside: +8.92%
Tandem Diabetes Care
Jan 9, 2026
Maintains: Market Perform
Price Target: $18 → $25
Current: $18.61
Upside: +34.34%
Stryker
Jan 9, 2026
Maintains: Outperform
Price Target: $450 → $465
Current: $331.54
Upside: +40.25%
Medtronic
Jan 9, 2026
Maintains: Outperform
Price Target: $111 → $112
Current: $86.63
Upside: +29.29%
Johnson & Johnson
Jan 9, 2026
Maintains: Market Perform
Price Target: $193 → $208
Current: $243.04
Upside: -14.42%
DexCom
Jan 9, 2026
Maintains: Outperform
Price Target: $84 → $86
Current: $62.22
Upside: +38.22%
Oct 24, 2024
Maintains: Outperform
Price Target: $92 → $100
Current: $62.82
Upside: +59.18%
Mar 16, 2022
Upgrades: Outperform
Price Target: $132 → $135
Current: $81.05
Upside: +66.56%